Group 3 innate lymphoid cells in intestinal health and disease
Nature Reviews Gastroenterology & Hepatology · 2024-06 · 21 (6) · 428-443
DOI: 10.1038/s41575-024-00906-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Gastroenterology & Hepatology, online erschienen am 11.03.2024. Verfasst von Veronika Horn und 1 weiteren Autor:innen. Beteiligte Einrichtung: Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA. Hauptthemen laut MEDLINE: Immunity, Innate, Lymphocytes. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
The gastrointestinal tract is an immunologically rich organ, containing complex cell networks and dense lymphoid structures that safeguard this large absorptive barrier from pathogens, contribute to tissue physiology and support mucosal healing. Simultaneously, the immune system must remain tolerant to innocuous dietary antigens and trillions of normally beneficial microorganisms colonizing the intestine. Indeed, a dysfunctional immune response in the intestine underlies the pathogenesis of numerous local and systemic diseases, including inflammatory bowel disease, food allergy, chronic enteric infections or cancers. Here, we discuss group 3 innate lymphoid cells (ILC3s), which have emerged as orchestrators of tissue physiology, immunity, inflammation, tolerance and malignancy in the gastrointestinal tract. ILC3s are abundant in the developing and healthy intestine but their numbers or function are altered during chronic disease and cancer. The latest studies provide new insights into the mechanisms by which ILC3s fundamentally shape intestinal homeostasis or disease pathophysiology, and often this functional dichotomy depends on context and complex interactions with other cell types or microorganisms. Finally, we consider how this knowledge could be harnessed to improve current treatments or provoke new opportunities for therapeutic intervention to promote gut health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.
- Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
- Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
- Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA. gfsonnenberg@med.cornell.edu.
- Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY, USA. gfsonnenberg@med.cornell.edu.
- Department of Microbiology & Immunology, Weill Cornell Medicine, Cornell University, New York, NY, USA. gfsonnenberg@med.cornell.edu.
Förderung
- NCI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Horn, V., & Sonnenberg, G. F. (2024). Group 3 innate lymphoid cells in intestinal health and disease. Nature Reviews Gastroenterology & Hepatology, 21(6), 428-443. https://doi.org/10.1038/s41575-024-00906-3
Vancouver
Horn V, Sonnenberg GF. Group 3 innate lymphoid cells in intestinal health and disease. Nature Reviews Gastroenterology & Hepatology. 2024;21(6):428-443. doi:10.1038/s41575-024-00906-3
BibTeX
@article{Horn2024,
author = {Horn, Veronika and Sonnenberg, Gregory F},
title = {Group 3 innate lymphoid cells in intestinal health and disease},
journal = {Nature Reviews Gastroenterology & Hepatology},
year = {2024},
volume = {21},
number = {6},
pages = {428--443},
doi = {10.1038/s41575-024-00906-3}
}
EUVIMED